ES2612889T3 - Vectores adenovíricos oncolíticos y procedimientos y utilizaciones relacionados con los mismos - Google Patents

Vectores adenovíricos oncolíticos y procedimientos y utilizaciones relacionados con los mismos Download PDF

Info

Publication number
ES2612889T3
ES2612889T3 ES09796016.5T ES09796016T ES2612889T3 ES 2612889 T3 ES2612889 T3 ES 2612889T3 ES 09796016 T ES09796016 T ES 09796016T ES 2612889 T3 ES2612889 T3 ES 2612889T3
Authority
ES
Spain
Prior art keywords
cells
metastasis
oncolytic adenoviral
region
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09796016.5T
Other languages
English (en)
Spanish (es)
Inventor
Akseli Hemminki
Anna Kanerva
Vincenzo Cerullo
Sari Pesonen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targovax Oy
Original Assignee
Targovax Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20080671A external-priority patent/FI20080671A0/fi
Application filed by Targovax Oy filed Critical Targovax Oy
Application granted granted Critical
Publication of ES2612889T3 publication Critical patent/ES2612889T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES09796016.5T 2008-12-22 2009-12-21 Vectores adenovíricos oncolíticos y procedimientos y utilizaciones relacionados con los mismos Active ES2612889T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
FI20080671A FI20080671A0 (fi) 2008-12-22 2008-12-22 Onkolyyttiset virukset
FI20080671 2008-12-22
FI20095466A FI121508B (fi) 2008-12-22 2009-04-27 Adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä
FI20095466 2009-04-27
US58597109A 2009-09-29 2009-09-29
US585971 2009-09-29
PCT/FI2009/051025 WO2010072900A1 (en) 2008-12-22 2009-12-21 Oncolytic adenoviral vectors and methods and uses related thereto

Publications (1)

Publication Number Publication Date
ES2612889T3 true ES2612889T3 (es) 2017-05-19

Family

ID=44502296

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09796016.5T Active ES2612889T3 (es) 2008-12-22 2009-12-21 Vectores adenovíricos oncolíticos y procedimientos y utilizaciones relacionados con los mismos

Country Status (20)

Country Link
EP (1) EP2379586B1 (enExample)
JP (2) JP2012513209A (enExample)
KR (1) KR101761094B1 (enExample)
CN (1) CN102264760B (enExample)
AU (1) AU2009332883B2 (enExample)
BR (1) BRPI0924123B8 (enExample)
CA (1) CA2748180C (enExample)
CY (1) CY1120039T1 (enExample)
DK (1) DK2379586T3 (enExample)
ES (1) ES2612889T3 (enExample)
HR (1) HRP20170165T1 (enExample)
HU (1) HUE031689T2 (enExample)
LT (1) LT2379586T (enExample)
PL (1) PL2379586T3 (enExample)
PT (1) PT2379586T (enExample)
RU (1) RU2520823C2 (enExample)
SG (1) SG173432A1 (enExample)
SI (1) SI2379586T1 (enExample)
WO (1) WO2010072900A1 (enExample)
ZA (1) ZA201104224B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2510088B1 (en) 2009-12-10 2016-10-05 Ottawa Hospital Research Institute Oncolytic rhabdovirus
EP2619312A1 (en) * 2010-09-24 2013-07-31 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies
EP2619224A1 (en) * 2010-09-24 2013-07-31 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
FI123955B (en) 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus
EP2806883B1 (en) 2012-01-25 2019-04-24 DNAtrix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
WO2014127478A1 (en) 2013-02-21 2014-08-28 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
CA2903582C (en) 2013-03-14 2021-06-08 Salk Institute For Biological Studies Oncolytic adenovirus compositions
US12421502B2 (en) 2013-04-18 2025-09-23 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
WO2014170389A1 (en) * 2013-04-18 2014-10-23 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
US10350275B2 (en) * 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
ES2987442T3 (es) 2015-05-04 2024-11-14 Theriva Biologics S L Adenovirus oncolíticos con mutaciones en epítopos de adenovirus inmunodominantes y su uso en el tratamiento del cáncer
FI127460B (en) 2016-01-15 2018-06-29 Targovax Oy Combining adenovirus and chemotherapeutic agents for treating cancer
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
WO2017156349A1 (en) 2016-03-10 2017-09-14 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
HUE053236T2 (hu) 2016-09-12 2021-06-28 Targovax Oy Adenovírus és ellenõrzõpont-gátlók kombinálása rák kezelésére
WO2018085461A1 (en) * 2016-11-01 2018-05-11 Dnatrix, Inc. Combination therapy for treatment of brain cancers
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CN108261426B (zh) * 2017-01-04 2019-04-05 杭州康万达医药科技有限公司 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用
KR20190104051A (ko) * 2017-01-06 2019-09-05 스타빌리테크 바이오파마 리미티드 바이러스
EP4599893A3 (en) 2017-04-14 2025-11-05 CG Oncology, Inc. Cg0070 for treating bcg resistant bladder carcinoma in situ
CA3060573A1 (en) 2017-04-21 2018-10-25 Baylor College Of Medicine Oncolytic virotherapy and immunotherapy
KR20240132124A (ko) 2017-05-25 2024-09-02 유니버시티 오브 센트럴 플로리다 리서치 파운데이션, 인코포레이티드 천연 살해 세포에 의해 사멸하는 종양 세포를 감작시키기 위한 신규한 종양용해 바이러스
JP7277926B2 (ja) * 2017-11-08 2023-05-19 国立大学法人 鹿児島大学 安全を確保しながら転移性がんまで効果的に治療可能な、搭載する免疫誘導遺伝子の最適発現レベルを与える発現制御システムを有する腫瘍溶解性ウイルス（腫瘍溶解性免疫治療）
GB201804473D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy Modified oncolytic adenoviruses
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
EP3725322A1 (en) 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing granzyme and perforin
EP3725888A1 (en) 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing peptidylarginine deiminase and tissue inhibitor of metalloproteinase
EP3725323A1 (en) * 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
WO2021194183A1 (ko) * 2020-03-25 2021-09-30 ㈜큐리진 면역 회피성 항종양 아데노바이러스
CN111909962A (zh) * 2020-07-23 2020-11-10 药鼎(北京)国际细胞医学技术有限公司 一种治疗肝癌的病毒构建体及其用途和构建方法
CN118853767A (zh) * 2024-08-22 2024-10-29 华中科技大学同济医学院附属同济医院 一种新型溶瘤腺病毒载体及其构建方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU780231B2 (en) * 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
EP1181382B1 (en) * 1999-06-01 2005-03-23 The University of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
EP1228234A2 (en) * 2000-03-14 2002-08-07 Neurologix, Inc. Production of chimeric capsid vectors
AU2003265873A1 (en) * 2003-08-28 2005-04-14 Cell Genesys, Inc. Oncolytic adenoviral vectors encoding gm-csf
ES2276623B1 (es) * 2005-12-12 2008-06-01 Proyecto De Biomedicina Cima, S.L Nuevos adenovirus recombinantes de replicacion condicionada (crad).
US20070292396A1 (en) 2006-03-02 2007-12-20 Juan Fueyo Combination therapy with oncolytic adenovirus

Also Published As

Publication number Publication date
AU2009332883B2 (en) 2015-05-21
CA2748180C (en) 2017-06-20
LT2379586T (lt) 2017-03-10
WO2010072900A1 (en) 2010-07-01
CY1120039T1 (el) 2018-12-12
CA2748180A1 (en) 2010-07-01
ZA201104224B (en) 2012-09-26
CN102264760B (zh) 2017-03-22
BRPI0924123B1 (pt) 2020-10-20
JP6280084B2 (ja) 2018-02-14
HUE031689T2 (en) 2017-07-28
EP2379586A1 (en) 2011-10-26
BRPI0924123B8 (pt) 2021-05-25
RU2011130511A (ru) 2013-01-27
EP2379586B1 (en) 2016-11-02
PT2379586T (pt) 2017-02-09
JP2012513209A (ja) 2012-06-14
HRP20170165T1 (hr) 2017-04-07
KR20110096579A (ko) 2011-08-30
CN102264760A (zh) 2011-11-30
SG173432A1 (en) 2011-09-29
DK2379586T3 (en) 2017-02-06
JP2016019530A (ja) 2016-02-04
RU2520823C2 (ru) 2014-06-27
AU2009332883A1 (en) 2011-07-07
KR101761094B1 (ko) 2017-08-04
PL2379586T3 (pl) 2017-08-31
SI2379586T1 (sl) 2017-02-28

Similar Documents

Publication Publication Date Title
ES2612889T3 (es) Vectores adenovíricos oncolíticos y procedimientos y utilizaciones relacionados con los mismos
JP7564572B2 (ja) 単離された組換え体腫瘍溶解性ワクシニアウイルスとｎｋ細胞を含む治療薬、その使用およびそれを適用したキット
Freeman et al. The Treatment of Ovarian Cancer with a Gene Modified Cancer Vaccine: A Phase I Study. Tulane University, New Orleans, Louisiana
CN107793482A (zh) 嵌合抗原受体及其基因和重组表达载体、car133‑nkt 细胞及其制备方法和应用
CN108060132A (zh) 一种基于肿瘤细胞与肿瘤相关成纤维细胞的3d共培养模型
JP2020503343A (ja) 治療剤、ならびに腫瘍および／またはがんの治療のための薬物のためのその使用
Bokemeyer et al. Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose-intensive chemotherapy
TWI439275B (zh) 一種人類自然殺手細胞之體外增殖方法
WO2021135984A1 (zh) 一种有限代数的滋养细胞的制备方法、snk细胞的培养方法和治疗肿瘤的方法
Wang et al. Combination of oxymatrine (Om) and astragaloside IV (As) enhances the infiltration and function of TILs in triple-negative breast cancer (TNBC)
CN108078978A (zh) 欧当归内酯a在制备肿瘤化疗药物增敏剂中的应用
Bodeker Integrative oncology meets immunotherapy: new prospects for combination therapy grounded in Eastern medical knowledge
CN111000851B (zh) 丹参酮i在制备肿瘤细胞自噬诱导剂药物中的应用
CN105950662A (zh) 一种靶向cd22的复制缺陷性重组慢病毒car-t转基因载体及其构建方法和应用
Fujisawa et al. Adjuvant immunotherapy of primary resected lung cancer with transfer factor
CN110205293A (zh) 一种加强型高效治疗肺癌的nk免疫细胞的制备方法及应用
CN116650474B (zh) 苍耳亭的医药新用途
CN116712447A (zh) 淫羊藿苷在微卫星稳定型肿瘤中的应用
CN111939262A (zh) 一种治疗肿瘤或癌症的药物组合物和其应用
CN115350176A (zh) 一种胃癌肿瘤细胞和胃癌肿瘤干细胞治疗药物及其应用
CN115212216A (zh) 抗食管鳞癌的药物组合物
CN118436669A (zh) 一种抗胰腺癌肿瘤药物组合物及其应用
RU2348420C2 (ru) Способ лечения местно-распространенного рака легкого
CN107693790A (zh) 用于肺癌治疗的联合药物
CN105920604A (zh) 用于治疗白血病的联合用药物及其在治疗白血病中的应用